-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the KRAS target competition, Amgen took the lead in crossing the finish line in May this year.
Lumakras (sotorasib) developed by Amgen was approved by the FDA for the treatment of non-small cell lung cancer (NSCLC) patients whose tumors carry the KRAS G12C mutation
.
Currently in a far leading position
Amgen non-small cell lung cancer
As a competitor of Amgen , Mirati has experienced an ups and downs journey.
After adagrasib has been awarded a breakthrough therapy certification for the treatment of KRAS G12C mutant non-small cell lung cancer that has received systemic treatment in the past, adagrasib plans to release it in 2021.
In the fourth quarter, the market application for the adapted new drug was submitted in the United States
.
A latecomer in this field, Cardiff Oncology evades its edge: on September 8th, it announced the early data of its drug candidate onvansertib on metastatic colorectal cancer (mCRC) , showing that compared with the standard of treatment, partial response and no disease progression prolonged Lifetime
.
According to information released by Cardiff, onvansertib is being tested in a Phase 1b/2 study in patients with metastatic colorectal cancer with KRAS gene mutations
.
The therapy is being combined with chemotherapy and Roche's bevacizumab, and patients must fail chemotherapy and//bevacizumab before entering the trial
Onvansertib achieved an initial partial response in 8 of 19 patients (42%) who received a moderate dose
.
After further follow-up, 7 patients (37%) were confirmed to have received treatment response
For all dose levels, 12 of 32 patients (ie, 38%) achieved partial remission, and 10 of 32 patients (ie, 31%) achieved confirmed remission
.
The trial has not yet reached the median progression-free survival, but the evaluable patients have reached 9.
4 months, and the historical length is 4.
5 to 5.
7 months
.
Onvansertib is well tolerated, but 10% of adverse events are reported as grade 3 or 4, which means they require medical intervention or hospitalization
.
Through supportive care, these events can be controlled and reversed
Cardiff is also testing the onvansertib combination in a Phase 2 study in patients with second-line metastatic pancreatic ductal adenocarcinoma and metastatic castration-resistant prostate cancer
.
Cardiff Oncology did not choose the fastest-growing and largest market (non-small cell lung cancer) such as competitor Amgen to promote research, but chose metastatic colorectal cancer and other indications as the research focus
.
Although competitors have made large development plans for their projects, including advanced colorectal cancer
Cardiff Oncology did not choose the fastest-growing and largest market (non-small cell lung cancer) such as competitor Amgen to promote research, but chose metastatic colorectal cancer and other indications as the research focus
